Nicotinamide Cognition Randomized Trial: What the Evidence Says

Quick Answer

Nicotinamide Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• In parallel, epidemiological evidence has consistently linked specific dietary patterns, such as the Mediterranean and MIND diets, to a reduced risk of cognitive decline and AD. [Kumari Ankita (2026); evidence level 2]
• These changes progress to reduced brain volume and are responsible for the memory loss associated with AD. [Kumari Ankita (2026); evidence level 2]
• This study provides evidence on the effects of 2000 mg/day NR supplementation on NAD+ levels and cognitive functioning (objective and subjective), sleep quality, fatigue severity, and mood symptoms (depression, anxiety) in individuals experiencing long-COVID symptoms. [Wu Chao-Yi (2025); evidence level 2]
• In addition, a small randomized, open-label, placebo-controlled phase II trial investigating the effects of a combination of metabolic cofactors (NR,-serine, N-acetyl--cysteine, and-carnitine tartrate) in people during acute COVID-19 found that this combination significantly reduced symptom duration.However, since NR was administered alongside other cofactors, its independent effects remain unclear. [Wu Chao-Yi (2025); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For nicotinamide cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kumari Ankita (2026). Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. DOI: 10.3390/nu18060907. PMCID: PMC13029159. PMID: 41901082. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029159/
• Wu Chao-Yi (2025). Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. DOI: 10.1016/j.eclinm.2025.103633. PMCID: PMC12675013. PMID: 41357333. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC12675013/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.